NCT05552690 is a NA clinical trial of blood draw in Thalassemia Trait, sponsored by Chiang Mai University.

Who is sponsoring NCT05552690?

NCT05552690 is sponsored by Chiang Mai University.

What drugs are being tested in NCT05552690?

Interventions in NCT05552690: blood draw.

What condition does NCT05552690 study?

NCT05552690 studies Thalassemia Trait, Thalassemia; Mixed.

Is NCT05552690 still recruiting?

NCT05552690 is currently status unknown. Last updated 8 February 2023.

Last reviewed 2023-02-08 · How we verify

NCT05552690

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Thalassemia Screening by Third Generation Sequencing

Status unknown NA Last updated 8 February 2023

What this trial tests

NA trial testing blood draw in Thalassemia Trait in 20 participants. Status unknown.

Timeline

1 February 2022

Primary endpoint
30 April 2022

31 May 2023

Quick facts

Lead sponsor	Chiang Mai University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	20
Start date	1 February 2022
Primary completion	30 April 2022
Estimated completion	31 May 2023
Sites	1 location across Thailand

Drugs / interventions tested

blood draw — full drug profile →

Conditions studied

Thalassemia Trait — all drugs for Thalassemia Trait →
Thalassemia; Mixed — all drugs for Thalassemia; Mixed →

Sponsor

Chiang Mai University

Who can join

Eligibility, any sex, with Thalassemia Trait or Thalassemia; Mixed. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Test globin gene in participants

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of blood draw

Trials testing the same drug.

NCT07251179 — Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies · not yet recruiting
NCT07132788 — Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass · active not recruiting
NCT06660108 — MOLECULAR BASIS OF LANGUAGE DEVELOPMENT AND ASSOCIATED DISORDERS · NA · recruiting
NCT06838806 — Epigenetic Nucleosomes in Plasma for Pulmonary Nodule Differentiation · recruiting
NCT06779032 — Clinical Profile of Skin Aging Based on Dermoscopy Photoaging Scale and Glogau Scale - Study of Leucocyte Telomere Lengt · not yet recruiting

Other Chiang Mai University trials

Trials by the same sponsor.

NCT07366775 — A Telenursing Program to Support Diabetes Self-Management · NA · active not recruiting
NCT07032610 — Long-term Immunogenicity of L-HAV Vaccine Among Healthy Thai Children and Adolescents · not yet recruiting
NCT06978621 — Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV · Phase 3 · recruiting
NCT06905041 — Preoperative Anemia Affected to Postoperative Outcomes in Liver Resection · not yet recruiting
NCT07476404 — Re-bleeding in Giant Meningioma and Intraoperative Hydroxyethyl Starch (HES) Fluid Therapy · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05552690 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chiang Mai University
Last refreshed: 8 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05552690.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing